

SMRTNI SLUČAJEVI I TEŠKA OŠTEĆENJA KOD DJECE I MLADIH NAKON CIJEPLJENJA COVID-19 CJEPIVOM -IZVJEŠĆA I REFERENCE-

(ažurirano 19.01.2022)

SMRTNI SLUČAJEVI

izvor: VAERS baza podatak (do prosinca 17, 2021).

Medicinske prijave na poveznicama detaljno opisuju slučajeve smrti i vrijeme koje je prošlo od cijepljenja – prosudite sami

Ovi pedijatrijski slučajevi pronađeni su u VAERS (Vaccine Adverse Event Reporting System) sustavu. Smrtni slučajevi zbog samoubojstva su isključeni iz ove liste. Kod većine preminulih nije bilo drugih komorbiditeta te se radilo o zdravoj djeci, a slučajevi kod koji su komorbiditeti bili prisutni ti komorbiditeti se ne mogu izravno povezati s uzrokom smrti ili pak ukazuju na opasnost neselektivne primjene cjepiva kod djece s komorbiditetima.

Vjerodostojnost svih prijava je potvrđena (prijave su poslone od strane liječnika ili medicinskog osoblja). Prijave koje su poslone u VAERS od strane roditelja ili članova obitelji nisu uključene u ovu listu.

1. 16 godina (ž), 9 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1225942>
2. 15 godina (m), 1 dan nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1242573>
3. 15 godina (m), 23 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1382906>
4. 16 godina (m), 4 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1386841>
5. 17 godina (ž), 15 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1388042>
6. 13 godina (m), 1 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1406840>
7. 17 godina (ž), 6 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1420762>
8. 13 godina (m), 17 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1431289>
Radi zastoja srca u ED. Radi zastoja koji se ispostavilo da je posljedica intracerebralnog krvarenja (pripisuje se arteriovenskoj malformaciji ili tumoru), reanimiran, ponovo aretirao, moždana smrt proglašena slijedeće jutro. Pri prijemu u Hitnu uzet mu je uzorak za bris koji je došao pozitivan. Cijepljen 17 dana prije.
9. 16 godina (m), 6 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1475434>
10. 15 godina (m), 4 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1498080>
(Imao Covid u travnju 2021, u svibnju dijagnosticirana hipertrofična kardiomiopatija. Već u srpnju, 4 dana prije nego što je umro, dobiva drugu dozu. Nije razvidno kad je bila prva doza)

11. 13 godina (ž), 26 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1505250>
12. 16 godina (ž), 9 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1694568>
(komorbiditet: astma – Plućna embolija potvrđena autopsijom)
13. 16 godina (m), 23 dana nakon Pfizer injekcije <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1734141>
14. 16 godina (ž), 1 dan nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1757635>
15. 15 godina (m), 6 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1764974>
16. 13 godina (ž), 15 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1815096>
(komorbiditet: Astma – uzrok smrti: Zastoj srca.
17. 17 godina (ž), 36 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1828901>
18. 16 godina (ž), 9 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1854668>
(komorbiditet: Karcinom pločastih stanica pluća – uzrok smrti: obilno krvarenje s brojnim vaginalnim ugrušcima
19. 5 godina (ž), 4 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1890705>
(komorbiditet: hidrocefalus, spastična moždana klijenut - uzrok smrti nepoznat – pronađena mrtva četvrto ujutro nakon cijepjenja)
20. 15 godina (ž), istog dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1592684>
(komorbiditet: Sy Barlowi - prolaps mitralnog zaliska. Uzroci smrti (autopsija - Srčani zastoj. Anoksija mozga)
21. 14 godina (ž), 28 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1690103>
22. 16 godina (m), 6 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1702154>
23. 16 godina (ž), nepoznato dana nakon Pfizer cj: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1732657>
24. 17 godina (m), 9 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1737907>
(komorbiditet: Down sindrom – uzrok smrti – Nespecificirana pneumonija, plućna sepsa, septični šok i COVID19)
25. 15 godina (m), isti dan nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1845034>
26. 13 godina (m), isti dan nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1862946>
(komorbiditet: Bronhijalna astma – uzrok Zatajenje srca i pluća – obdukcijski nalaz ne potvrđuje utapanje kao uzrok)
27. 12 godina (m), isti dan nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1865979>
(komorbiditet: prirodene kontrakture ili Artrogripoza, Kardiomiopatija (komorbiditet otkriven autopsijom). Uzrok smrti - srčana smrt odnosno zastoj)
28. 13 godina (ž), 31 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1913198>
29. 17 godina (m), 7 dana nakon Pfizer injekcije: <https://medalerts.org/vaersdb/findfield.php?IDNUMBER=1953860>

Poveznice se mogu potvrditi korištenjem pretrage na ovoj poveznici: <https://openvaers.com/openvaers>
Unesite zadnjih 7 brojeva iz gore navedenih poveznice u VERS bazi podatak.

Dodatne poveznice:

1. [Smrt šesnaestogodišnjaka 5 dana nakon cijepljenja COVID cjevivom- Smrt zbog cijepljenja: potvrđena od strane patologa i kardiologa.](#)
2. [Smrt petog studenta nakon primanja Pfizer COVID cjeviva u Vijetnamu.](#)
3. [Vlasti u Novom Zelandu povezuju smrt 26-godišnjaka s Pfizer COVID cjevivom](#)
4. [Smrt srednjoškolca nakon primanja COVID-19 Cjeviva \(Vijetnam\)](#)
5. [Smrt tinejdžera od zatajenja srca tjednima nakon primanja Pfizer COVID cjeviva.](#)

NUSPOJAVE I SMRTNI SLUČAJEVI NAKON COVID-19 CJEPIVA KOD MLADIH I SPORTAŠA

[Popis 298 teško oštećenih ili umrlih sportaša i mladih ljudi](#) povezanih s cjevivom COVID 19
- ovi slučajevi nisu neovisno provjereni

NUSPOJAVE COVID-19 CJEPIVA KOJA MOGU NAŠTETI DJECI

Znanstveni radovi, reference i izvješća koja ukazuju na opasnosti COVID cjeviva za djecu

1. Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients. *Int J Cardiol*, 340, 119-121. doi:10.1016/j.ijcard.2021.08.018. <https://www.ncbi.nlm.nih.gov/pubmed/34416319>
2. Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Myocarditis following COVID-19 mRNA vaccination. *Vaccine*, 39(29), 3790-3793. doi:10.1016/j.vaccine.2021.05.087. <https://www.ncbi.nlm.nih.gov/pubmed/34092429>
3. Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Myocarditis following COVID-19 vaccination. *Radiol Case Rep*, 16(8), 2142-2145. doi:10.1016/j.radcr.2021.05.033. <https://www.ncbi.nlm.nih.gov/pubmed/34025885>
4. Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination. *QJM*. doi:10.1093/qjmed/hcab252. <https://www.ncbi.nlm.nih.gov/pubmed/34586408>
5. Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine. *J Emerg Med*, 61(6), e129-e132. doi:10.1016/j.jemermed.2021.09.017. <https://www.ncbi.nlm.nih.gov/pubmed/34756746>
6. Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Myocarditis With COVID-19 mRNA Vaccines. *Circulation*, 144(6), 471-484. doi:10.1161/CIRCULATIONAHA.121.056135. <https://www.ncbi.nlm.nih.gov/pubmed/34281357>
7. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021). Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? *Vaccines (Basel)*, 9(11). doi:10.3390/vaccines9111353. <https://www.ncbi.nlm.nih.gov/pubmed/34835284>

8. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022). Concerning the unexpected prothrombotic state following some coronavirus disease 2019 vaccines. *J Cardiovasc Med (Hagerstown)*, 23(2), 71-74. doi:10.2459/JCM.0000000000001232. <https://www.ncbi.nlm.nih.gov/pubmed/34366403>
9. Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis. *Pediatr Rep*, 13(3), 530-533. doi:10.3390/pediatric13030061. <https://www.ncbi.nlm.nih.gov/pubmed/34564344>
10. Chai, Q., Nygaard, U., Schmidt, R. C., Zaremba, T., Moller, A. M., & Thorvig, C. M. (2022). Multisystem inflammatory syndrome in a male adolescent after his second Pfizer-BioNTech COVID-19 vaccine. *Acta Paediatr*, 111(1), 125-127. doi:10.1111/apa.16141. <https://www.ncbi.nlm.nih.gov/pubmed/34617315>
11. Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? *Clin Res Cardiol*, 110(11), 1850-1854. doi:10.1007/s00392-021-01916-w. <https://www.ncbi.nlm.nih.gov/pubmed/34333695>
12. Chan AC, Tan BY, Goh Y, Tan SS, Tambyah PA. Aseptic meningitis after BNT-162b2 COVID-19 vaccination. *Brain Behav Immun Health*. 2022 Feb;19:100406. doi: 10.1016/j.bbih.2021.100406. Epub 2021 Dec 13. PMID: 34927105; PMCID: PMC8667462. <https://www.sciencedirect.com/science/article/pii/S266635462100209X?via%3Dihub>
13. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. *Medicina (Kaunas)*, 57(11). doi:10.3390/medicina57111163. <https://www.ncbi.nlm.nih.gov/pubmed/34833382>
14. Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents. *AJR Am J Roentgenol*. doi:10.2214/AJR.21.26853. <https://www.ncbi.nlm.nih.gov/pubmed/34704459>
15. Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. *J Korean Med Sci*, 36(40), e286. doi:10.3346/jkms.2021.36.e286. <https://www.ncbi.nlm.nih.gov/pubmed/34664804>
16. Chouchana, L., Blet, A., Al-Khalaf, M., Kafil, T. S., Nair, G., Robblee, J., . . . Liu, P. P. (2021). Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. *Clin Pharmacol Ther*. doi:10.1002/cpt.2499. <https://www.ncbi.nlm.nih.gov/pubmed/34860360>
17. Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. *Clin Infect Dis*. doi:10.1093/cid/ciab989. <https://www.ncbi.nlm.nih.gov/pubmed/34849657>
18. Clarke, R., & Ioannou, A. (2021). Should T2 mapping be used in cases of recurrent myocarditis to differentiate between the acute inflammation and chronic scar? *J Pediatr*. doi:10.1016/j.jpeds.2021.12.026. <https://www.ncbi.nlm.nih.gov/pubmed/34933012>
19. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., . . . Bruno, R. (2021). COVID vaccination and asthma exacerbation: might there be a link? *Int J Infect Dis*, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. <https://www.ncbi.nlm.nih.gov/pubmed/34547487>
20. Das, B. B., Kohli, U., Ramachandran, P., Nguyen, H. H., Greil, G., Hussain, T., . . . Khan, D. (2021). Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age. *J Pediatr*, 238, 26-32 e21. doi:10.1016/j.jpeds.2021.07.044. <https://www.ncbi.nlm.nih.gov/pubmed/34339728>
21. Deb, A., Abdelmalek, J., Iwuji, K., & Nugent, K. (2021). Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. *J Prim Care Community Health*, 12, 21501327211029230. doi:10.1177/21501327211029230. <https://www.ncbi.nlm.nih.gov/pubmed/34219532>
22. Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2. *JACC Cardiovasc Imaging*, 14(9), 1862-1863. doi:10.1016/j.jcmg.2021.06.003. <https://www.ncbi.nlm.nih.gov/pubmed/34246585>

23. Dimopoulou, D., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021). Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors. *Arthritis Rheumatol*. doi:10.1002/art.41977. <https://www.ncbi.nlm.nih.gov/pubmed/34492161>
24. Dimopoulou, D., Vartzelis, G., Dasoula, F., Tsolia, M., & Maritsi, D. (2021). Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. *Ann Rheum Dis*. doi:10.1136/annrheumdis-2021-221607. <https://www.ncbi.nlm.nih.gov/pubmed/34844930>
25. Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report. *Clin Res Cardiol*, 110(11), 1855-1859. doi:10.1007/s00392-021-01936-6. <https://www.ncbi.nlm.nih.gov/pubmed/34487236>
26. Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). [Acute myocarditis in a young adult two days after Pfizer vaccination]. *G Ital Cardiol (Rome)*, 22(11), 891-893. doi:10.1714/3689.36746. <https://www.ncbi.nlm.nih.gov/pubmed/34709227>
27. Fazlollahi, A., Zahmatyar, M., Noori, M., Nejadghaderi, S. A., Sullman, M. J. M., Shekarriz-Foumani, R., . . . Safiri, S. (2021). Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. *Rev Med Virol*, e2318. doi:10.1002/rmv.2318. <https://www.ncbi.nlm.nih.gov/pubmed/34921468>
28. Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines. *Eur Heart J Qual Care Clin Outcomes*. doi:10.1093/ehjqcco/qcab090. <https://www.ncbi.nlm.nih.gov/pubmed/34849667>
29. Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021). SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naive and Pre-Immune Humans. *Front Immunol*, 12, 728021. doi:10.3389/fimmu.2021.728021. <https://www.ncbi.nlm.nih.gov/pubmed/34646267>
30. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., . . . Elkayam, O. (2021). Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis*, 80(10), 1330-1338. doi:10.1136/annrheumdis-2021-220647. <https://www.ncbi.nlm.nih.gov/pubmed/34127481>
31. Gatti, M., Raschi, E., Moretti, U., Ardizzoni, A., Poluzzi, E., & Diemberger, I. (2021). Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. *Vaccines (Basel)*, 9(1). doi:10.3390/vaccines9010019. <https://www.ncbi.nlm.nih.gov/pubmed/33406694>
32. Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al'Aref, S. (2021). A Late Presentation of COVID-19 Vaccine-Induced Myocarditis. *Cureus*, 13(9), e17890. doi:10.7759/cureus.17890. <https://www.ncbi.nlm.nih.gov/pubmed/34660088>
33. Gellad, W. F. (2021). Myocarditis after vaccination against covid-19. *BMJ*, 375, n3090. doi:10.1136/bmj.n3090. <https://www.ncbi.nlm.nih.gov/pubmed/34916217>
34. Greenhawt, M., Abrams, E. M., Shaker, M., Chu, D. K., Khan, D., Akin, C., . . . Golden, D. B. K. (2021). The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. *J Allergy Clin Immunol Pract*, 9(10), 3546-3567. doi:10.1016/j.jaip.2021.06.006. <https://www.ncbi.nlm.nih.gov/pubmed/34153517>
35. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. *BMC Cardiovasc Disord*, 21(1), 375. doi:10.1186/s12872-021-02183-3. <https://www.ncbi.nlm.nih.gov/pubmed/34348657>
36. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., . . . Shay, D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. *MMWR Morb Mortal Wkly Rep*, 70(31), 1053-1058. doi:10.15585/mmwr.mm7031e1. <https://www.ncbi.nlm.nih.gov/pubmed/34351881>

37. Helms, J. M., Ansteatt, K. T., Roberts, J. C., Kamatam, S., Foong, K. S., Labayog, J. S., & Tarantino, M. D. (2021). Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine. *J Blood Med*, 12, 221-224. doi:10.2147/JBM.S307047. <https://www.ncbi.nlm.nih.gov/pubmed/33854395>
38. Hippisley-Cox, J., Patone, M., Mei, X. W., Saatci, D., Dixon, S., Khunti, K., . . . Coupland, C. A. C. (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. *BMJ*, 374, n1931. doi:10.1136/bmj.n1931. <https://www.ncbi.nlm.nih.gov/pubmed/34446426>
39. Ho, J. S., Sia, C. H., Ngiam, J. N., Loh, P. H., Chew, N. W., Kong, W. K., & Poh, K. K. (2021). A review of COVID-19 vaccination and the reported cardiac manifestations. *Singapore Med J*. doi:10.11622/smedj.2021210. <https://www.ncbi.nlm.nih.gov/pubmed/34808708>
40. Iguchi, T., Umeda, H., Kojima, M., Kanno, Y., Tanaka, Y., Kinoshita, N., & Sato, D. (2021). Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report. *Drug Saf*, 44(11), 1209-1214. doi:10.1007/s40264-021-01104-9. <https://www.ncbi.nlm.nih.gov/pubmed/34347278>
41. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). *Med Lett Drugs Ther*, 63(1629), e9. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/34544112><https://www.ncbi.nlm.nih.gov/pubmed/34544112>
42. Ioannou, A. (2021a). Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. *QJM*. doi:10.1093/qjmed/hcab231. <https://www.ncbi.nlm.nih.gov/pubmed/34463755>
43. Ioannou, A. (2021b). T2 mapping should be utilised in cases of suspected myocarditis to confirm an acute inflammatory process. *QJM*. doi:10.1093/qjmed/hcab326. <https://www.ncbi.nlm.nih.gov/pubmed/34931681>
44. Isaak, A., Feisst, A., & Lutkens, J. A. (2021). Myocarditis Following COVID-19 Vaccination. *Radiology*, 301(1), E378-E379. doi:10.1148/radiol.2021211766. <https://www.ncbi.nlm.nih.gov/pubmed/34342500>
45. Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeier, A. B. (2021). Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. *Glob Cardiol Sci Pract*, 2021(3), e202118. doi:10.21542/gcsp.2021.18. <https://www.ncbi.nlm.nih.gov/pubmed/34805376>
46. Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). COVID-19 Vaccination-Associated Myocarditis in Adolescents. *Pediatrics*, 148(5). doi:10.1542/peds.2021-053427. <https://www.ncbi.nlm.nih.gov/pubmed/34389692>
47. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. *J Pediatric Infect Dis Soc*, 10(10), 937-939. doi:10.1093/jpids/piab061. <https://www.ncbi.nlm.nih.gov/pubmed/34270752>
- 48.
49. Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). *Circ J*. doi:10.1253/circj.CJ-21-0818. <https://www.ncbi.nlm.nih.gov/pubmed/34744118>
50. Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Myocarditis following COVID-19 vaccination. *Int J Cardiol Heart Vasc*, 36, 100872. doi:10.1016/j.ijcha.2021.100872. <https://www.ncbi.nlm.nih.gov/pubmed/34568540>
51. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. *Cureus*, 13(7), e16590. doi:10.7759/cureus.16590. <https://www.ncbi.nlm.nih.gov/pubmed/34447639>
52. Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol*, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. <https://www.ncbi.nlm.nih.gov/pubmed/34185046>
53. Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. *J Korean Med Sci*, 36(32), e229. doi:10.3346/jkms.2021.36.e229. <https://www.ncbi.nlm.nih.gov/pubmed/34402228>

54. King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. *Am Heart J Plus*, 8, 100042. doi:10.1016/j.ahjo.2021.100042. <https://www.ncbi.nlm.nih.gov/pubmed/34396358>
55. Klein, N. P., Lewis, N., Goddard, K., Fireman, B., Zerbo, O., Hanson, K. E., . . . Weintraub, E. S. (2021). Surveillance for Adverse Events After COVID-19 mRNA Vaccination. *JAMA*, 326(14), 1390-1399. doi:10.1001/jama.2021.15072. <https://www.ncbi.nlm.nih.gov/pubmed/34477808>
56. Klimek, L., Bergmann, K. C., Brehler, R., Pfutzner, W., Zuberbier, T., Hartmann, K., . . . Worm, M. (2021). Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI. *Allergo J Int*, 1-17. doi:10.1007/s40629-021-00165-7. <https://www.ncbi.nlm.nih.gov/pubmed/33898162>
57. Klimek, L., Novak, N., Hamelmann, E., Werfel, T., Wagenmann, M., Taube, C., . . . Worm, M. (2021). Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA). *Allergo J Int*, 30(2), 51-55. doi:10.1007/s40629-020-00160-4. <https://www.ncbi.nlm.nih.gov/pubmed/33643776>
58. Kohli, U., Desai, L., Chowdhury, D., Harahsheh, A. S., Yonts, A. B., Ansong, A., . . . Ang, J. Y. (2021). mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study. *J Pediatr*. doi:10.1016/j.jpeds.2021.12.025. <https://www.ncbi.nlm.nih.gov/pubmed/34952008>
59. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021a). Erratum to "Why are we vaccinating children against COVID-19?" [*Toxicol. Rep.* 8C (2021) 1665-1684 / 1193]. *Toxicol Rep*, 8, 1981. doi:10.1016/j.toxrep.2021.10.003. <https://www.ncbi.nlm.nih.gov/pubmed/34642628>
60. Kostoff, R. N., Calina, D., Kanduc, D., Briggs, M. B., Vlachoyiannopoulos, P., Svistunov, A. A., & Tsatsakis, A. (2021b). Why are we vaccinating children against COVID-19? *Toxicol Rep*, 8, 1665-1684. doi:10.1016/j.toxrep.2021.08.010. <https://www.ncbi.nlm.nih.gov/pubmed/34540594>
61. Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). mRNA COVID vaccine and myocarditis in adolescents. *Hong Kong Med J*, 27(5), 326-327. doi:10.12809/hkmj215120. <https://www.ncbi.nlm.nih.gov/pubmed/34393110>
62. Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). Reply to "Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination". *QJM*. doi:10.1093/qjmed/hcab232. <https://www.ncbi.nlm.nih.gov/pubmed/34463770>
63. Lee, E. J., Cines, D. B., Gernsheimer, T., Kessler, C., Michel, M., Tarantino, M. D., . . . Bussel, J. B. (2021). Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. *Am J Hematol*, 96(5), 534-537. doi:10.1002/ajh.26132. <https://www.ncbi.nlm.nih.gov/pubmed/33606296>
64. Levin, D., Shimon, G., Fadlon-Deraï, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Myocarditis following COVID-19 vaccination - A case series. *Vaccine*, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004. <https://www.ncbi.nlm.nih.gov/pubmed/34535317>
65. Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. *J Pers Med*, 11(11). doi:10.3390/jpm11111106. <https://www.ncbi.nlm.nih.gov/pubmed/34834458>
66. Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. *Front Cardiovasc Med*, 8, 758996. doi:10.3389/fcvm.2021.758996. <https://www.ncbi.nlm.nih.gov/pubmed/34778411>
67. Long, S. S. (2021). Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents. *J Pediatr*, 238, 5. doi:10.1016/j.jpeds.2021.07.057. <https://www.ncbi.nlm.nih.gov/pubmed/34332972>
68. Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers.

- Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001.
<https://www.ncbi.nlm.nih.gov/pubmed/34375696>
69. Madelon, N., Lauper, K., Breville, G., Sabater Royo, I., Goldstein, R., Andrey, D. O., . . . Eberhardt, C. S. (2021). Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. *Clin Infect Dis*. doi:10.1093/cid/ciab954. <https://www.ncbi.nlm.nih.gov/pubmed/34791081>
 70. Mangat, C., & Milosavljevic, N. (2021). BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age. *Case Rep Pediatr*, 2021, 6901131. doi:10.1155/2021/6901131. <https://www.ncbi.nlm.nih.gov/pubmed/34676123>
 71. Mark, C., Gupta, S., Punnett, A., Upton, J., Orkin, J., Atkinson, A., . . . Alexander, S. (2021). Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. *Pediatr Blood Cancer*, 68(11), e29295. doi:10.1002/pbc.29295. <https://www.ncbi.nlm.nih.gov/pubmed/34398511>
 72. McLean, K., & Johnson, T. J. (2021). Myopericarditis in a previously healthy adolescent male following COVID-19 vaccination: A case report. *Acad Emerg Med*, 28(8), 918-921. doi:10.1111/acem.14322. <https://www.ncbi.nlm.nih.gov/pubmed/34133825>
 73. Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med*, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. <https://www.ncbi.nlm.nih.gov/pubmed/34614328>
 74. Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. *J Pediatr*, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035. <https://www.ncbi.nlm.nih.gov/pubmed/34166671>
 75. Mohamed, L., Madsen, A. M. R., Schaltz-Buchholzer, F., Ostenfeld, A., Netea, M. G., Benn, C. S., & Kofoed, P. E. (2021). Reactivation of BCG vaccination scars after vaccination with mRNA-Covid-vaccines: two case reports. *BMC Infect Dis*, 21(1), 1264. doi:10.1186/s12879-021-06949-0. <https://www.ncbi.nlm.nih.gov/pubmed/34930152>
 76. Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833. <https://www.ncbi.nlm.nih.gov/pubmed/34185045>
 77. Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. *Intern Med*. doi:10.2169/internalmedicine.8731-21. <https://www.ncbi.nlm.nih.gov/pubmed/34840235>
 78. Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. *J Cardiol Cases*. doi:10.1016/j.jccase.2021.11.006. <https://www.ncbi.nlm.nih.gov/pubmed/34876937>
 79. Ntouros, P. A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P., Tektonidou, M. G., . . . Sfikakis, P. P. (2021). Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. *Clin Immunol*, 229, 108765. doi:10.1016/j.clim.2021.108765. <https://www.ncbi.nlm.nih.gov/pubmed/34089859>
 80. Nygaard, U., Holm, M., Bohnstedt, C., Chai, Q., Schmidt, L. S., Hartling, U. B., . . . Stensballe, L. G. (2022). Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents. *Pediatr Infect Dis J*, 41(1), e25-e28. doi:10.1097/INF.0000000000003389. <https://www.ncbi.nlm.nih.gov/pubmed/34889875>
 81. Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study. *J Korean Med Sci*, 36(32), e232. doi:10.3346/jkms.2021.36.e232. <https://www.ncbi.nlm.nih.gov/pubmed/34402230>
 82. Park, J., Brekke, D. R., & Bratincsak, A. (2021). Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine. *Cardiol Young*, 1-4. doi:10.1017/S1047951121002547. <https://www.ncbi.nlm.nih.gov/pubmed/34180390>

83. Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series. *J Cardiovasc Magn Reson*, 23(1), 101. doi:10.1186/s12968-021-00795-4.
<https://www.ncbi.nlm.nih.gov/pubmed/34496880>
84. Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med*. doi:10.1038/s41591-021-01630-0.
<https://www.ncbi.nlm.nih.gov/pubmed/34907393>
85. Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection. *Radiol Case Rep*, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082.
<https://www.ncbi.nlm.nih.gov/pubmed/34367386>
86. Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination. *Clin Infect Dis*. doi:10.1093/cid/ciab926. <https://www.ncbi.nlm.nih.gov/pubmed/34734240>
87. Perrotta, A., Biondi-Zoccai, G., Saade, W., Miraldi, F., Morelli, A., Marullo, A. G., . . . Peruzzi, M. (2021). A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. *Panminerva Med*, 63(3), 324-331. doi:10.23736/S0031-0808.21.04435-9.
<https://www.ncbi.nlm.nih.gov/pubmed/34738774>
88. Sanchez Tijmes, F., Thavendiranathan, P., Udell, J. A., Seidman, M. A., & Hanneman, K. (2021). Cardiac MRI Assessment of Nonischemic Myocardial Inflammation: State of the Art Review and Update on Myocarditis Associated with COVID-19 Vaccination. *Radiol Cardiothorac Imaging*, 3(6), e210252. doi:10.1148/ryct.210252. <https://www.ncbi.nlm.nih.gov/pubmed/34934954>
89. Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. *J Pediatr*, 238, 317-320. doi:10.1016/j.jpeds.2021.06.083.
<https://www.ncbi.nlm.nih.gov/pubmed/34228985>
90. Schneider, J., Sottmann, L., Greinacher, A., Hagen, M., Kasper, H. U., Kuhnen, C., . . . Schmeling, A. (2021). Postmortem investigation of fatalities following vaccination with COVID-19 vaccines. *Int J Legal Med*, 135(6), 2335-2345. doi:10.1007/s00414-021-02706-9. <https://www.ncbi.nlm.nih.gov/pubmed/34591186>
91. Schramm, R., Costard-Jackle, A., Rivinius, R., Fischer, B., Muller, B., Boeken, U., . . . Gummert, J. (2021). Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. *Clin Res Cardiol*, 110(8), 1142-1149. doi:10.1007/s00392-021-01880-5.
<https://www.ncbi.nlm.nih.gov/pubmed/34241676>
92. Sessa, F., Salerno, M., Esposito, M., Di Nunno, N., Zamboni, P., & Pomara, C. (2021). Autopsy Findings and Causality Relationship between Death and COVID-19 Vaccination: A Systematic Review. *J Clin Med*, 10(24). doi:10.3390/jcm10245876. <https://www.ncbi.nlm.nih.gov/pubmed/34945172>
93. Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021). Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. *Front Immunol*, 12, 714170. doi:10.3389/fimmu.2021.714170. <https://www.ncbi.nlm.nih.gov/pubmed/34707602>
94. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. *Cureus*, 13(7), e16383. doi:10.7759/cureus.16383.
<https://www.ncbi.nlm.nih.gov/pubmed/34408937>
95. Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Myocarditis following COVID-19 vaccination: magnetic resonance imaging study. *Eur Heart J Cardiovasc Imaging*. doi:10.1093/ehjci/jeab230. <https://www.ncbi.nlm.nih.gov/pubmed/34739045>
96. Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older. *JAMA Intern Med*, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511. <https://www.ncbi.nlm.nih.gov/pubmed/34605853>

97. Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis. medRxiv. doi:10.1101/2021.07.23.21260998.
<https://www.ncbi.nlm.nih.gov/pubmed/34341797>
98. Smith, C., Odd, D., Harwood, R., Ward, J., Linney, M., Clark, M., . . . Fraser, L. K. (2021). Deaths in children and young people in England after SARS-CoV-2 infection during the first pandemic year. Nat Med. doi:10.1038/s41591-021-01578-1. <https://www.ncbi.nlm.nih.gov/pubmed/34764489>
99. Snapiri, O., Rosenberg Danziger, C., Shirman, N., Weissbach, A., Lowenthal, A., Ayalon, I., . . . Bilavsky, E. (2021). Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine. *Pediatr Infect Dis J*, 40(10), e360-e363. doi:10.1097/INF.0000000000003235.
<https://www.ncbi.nlm.nih.gov/pubmed/34077949>
100. Spinner, J. A., Julien, C. L., Olayinka, L., Dreyer, W. J., Bocchini, C. E., Munoz, F. M., & Devaraj, S. (2021). SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report. *J Heart Lung Transplant*. doi:10.1016/j.healun.2021.11.001. <https://www.ncbi.nlm.nih.gov/pubmed/34911654>
101. Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Myocarditis Associated with mRNA COVID-19 Vaccination. *Radiology*, 301(2), E409-E411. doi:10.1148/radiol.2021211430. <https://www.ncbi.nlm.nih.gov/pubmed/34282971>
102. Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review. *Cardiovasc Revasc Med*. doi:10.1016/j.carrev.2021.08.012. <https://www.ncbi.nlm.nih.gov/pubmed/34420869>
103. Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine. *Eur Heart J Case Rep*, 5(8), ytab319. doi:10.1093/ehjcr/ytab319.
<https://www.ncbi.nlm.nih.gov/pubmed/34514306><https://www.ncbi.nlm.nih.gov/pubmed/34955479>
104. Team, C. C.-R., Food, & Drug, A. (2021). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. *MMWR Morb Mortal Wkly Rep*, 70(2), 46-51. doi:10.15585/mmwr.mm7002e1. <https://www.ncbi.nlm.nih.gov/pubmed/33444297>
105. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. *Clin Med Insights Cardiol*, 15, 11795468211056634. doi:10.1177/11795468211056634. <https://www.ncbi.nlm.nih.gov/pubmed/34866957>
106. Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults. *Circulation*. doi:10.1161/CIRCULATIONAHA.121.056583.
<https://www.ncbi.nlm.nih.gov/pubmed/34865500>
107. Umei, T. C., Kishino, Y., Shiraishi, Y., Inohara, T., Yuasa, S., & Fukuda, K. (2021). Recurrence of myopericarditis following mRNA COVID-19 vaccination in a male adolescent. *CJC Open*. doi:10.1016/j.cjco.2021.12.002. <https://www.ncbi.nlm.nih.gov/pubmed/34904134>
108. Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines. *Cureus*, 13(6), e15576. doi:10.7759/cureus.15576. <https://www.ncbi.nlm.nih.gov/pubmed/34277198>
109. Visclosky, T., Theyyanni, N., Klekowski, N., & Bradin, S. (2021). Myocarditis Following mRNA COVID-19 Vaccine. *Pediatr Emerg Care*, 37(11), 583-584. doi:10.1097/PEC.0000000000002557.
<https://www.ncbi.nlm.nih.gov/pubmed/34731877>
110. Warren, C. M., Snow, T. T., Lee, A. S., Shah, M. M., Heider, A., Blomkalns, A., . . . Nadeau, K. C. (2021). Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. *JAMA Netw Open*, 4(9), e2125524. doi:10.1001/jamanetworkopen.2021.25524 .
111. Watkins, K., Griffin, G., Septaric, K., & Simon, E. L. (2021). Myocarditis after BNT162b2 vaccination in a healthy male. *Am J Emerg Med*, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051.
<https://www.ncbi.nlm.nih.gov/pubmed/34229940><https://www.ncbi.nlm.nih.gov/pubmed/34336774>
112. Welsh, K. J., Baumblatt, J., Chege, W., Goud, R., & Nair, N. (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event

- Reporting System (VAERS). *Vaccine*, 39(25), 3329-3332. doi:10.1016/j.vaccine.2021.04.054.
<https://www.ncbi.nlm.nih.gov/pubmed/34006408>
113. Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *N Engl J Med*, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737. <https://www.ncbi.nlm.nih.gov/pubmed/34614329>
 114. Zimmermann, P., & Curtis, N. (2020). Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. *Arch Dis Child*. doi:10.1136/archdischild-2020-320338. <https://www.ncbi.nlm.nih.gov/pubmed/33262177>
 115. Guillain-Barre Syndrome (GBS) and COVID-19 Vaccination References (As GBS affects all age cohorts - references are all age cohorts) Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tanasescu, R., & Evans, J. R. (2021).
 116. Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination. *Ann Neurol*, 90(2), 315-318. doi:10.1002/ana.26144. <https://www.ncbi.nlm.nih.gov/pubmed/34114269>
 117. Bouattour, N., Hdiji, O., Sakka, S., Fakhfakh, E., Moalla, K., Daoud, S., . . . Mhiri, C. (2021). Guillain-Barre syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. *Neurol Sci*. doi:10.1007/s10072-021-05733-x. <https://www.ncbi.nlm.nih.gov/pubmed/34796417>
 118. Censcak, D., Ungermann, L., Stetkarova, I., & Ehler, E. (2021). Guillan-Barre Syndrome after First Vaccination Dose against COVID-19: Case Report. *Acta Medica (Hradec Kralove)*, 64(3), 183-186. doi:10.14712/18059694.2021.31. <https://www.ncbi.nlm.nih.gov/pubmed/34779385>
 119. da Silva, G. F., da Silva, C. F., Oliveira, R., Romancini, F., Mendes, R. M., Locks, A., . . . Braatz, V. L. (2021). Guillain-Barre syndrome after coronavirus disease 2019 vaccine: A temporal association. *Clin Exp Neuroimmunol*. doi:10.1111/cen3.12678. <https://www.ncbi.nlm.nih.gov/pubmed/34900000>
 120. Guillain-Barre Syndrome Eight Days after Vector-Based COVID-19 Vaccination. *Case Rep Infect Dis*, 2021, 3619131. doi:10.1155/2021/3619131. <https://www.ncbi.nlm.nih.gov/pubmed/34055430>
 121. Finsterer, J. (2021b). Guillain-Barre syndrome 15 days after COVID-19 despite SARS-CoV-2 vaccination. *IDCases*, 25, e01226. doi:10.1016/j.idcr.2021.e01226. <https://www.ncbi.nlm.nih.gov/pubmed/34290962>
 122. Finsterer, J. (2021d). SARS-CoV-2 vaccinations may not only be complicated by GBS but also by distal small fibre neuropathy. *J Neuroimmunol*, 360, 577703. doi:10.1016/j.jneuroim.2021.577703. <https://www.ncbi.nlm.nih.gov/pubmed/34525410>
 123. Finsterer, J. (2022). Neurological side effects of SARS-CoV-2 vaccinations. *Acta Neurol Scand*, 145(1), 5-9. doi:10.1111/ane.13550. <https://www.ncbi.nlm.nih.gov/pubmed/34750810>
 124. Finsterer, J., Scorza, F. A., & Scorza, C. A. (2021). Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. *Clinics (Sao Paulo)*, 76, e3286. doi:10.6061/clinics/2021/e3286. <https://www.ncbi.nlm.nih.gov/pubmed/34644738>
 125. Hasan, T., Khan, M., Khan, F., & Hamza, G. (2021). Case of Guillain-Barre syndrome following COVID-19 vaccine. *BMJ Case Rep*, 14(6). doi:10.1136/bcr-2021-243629. <https://www.ncbi.nlm.nih.gov/pubmed/34187803>
 126. Kanabar, G., & Wilkinson, P. (2021). Guillain-Barre syndrome presenting with facial diplegia following COVID-19 vaccination in two patients. *BMJ Case Rep*, 14(10). doi:10.1136/bcr-2021-244527. <https://www.ncbi.nlm.nih.gov/pubmed/34649856>
 127. Koike, H., Chiba, A., & Katsuno, M. (2021). Emerging Infection, Vaccination, and Guillain-Barre Syndrome: A Review. *Neurol Ther*, 10(2), 523-537. doi:10.1007/s40120-021-00261-4. <https://www.ncbi.nlm.nih.gov/pubmed/34117994>
 128. Koike, H., & Katsuno, M. (2021). Emerging infectious diseases, vaccines and Guillain-Barre syndrome. *Clin Exp Neuroimmunol*. doi:10.1111/cen3.12644. <https://www.ncbi.nlm.nih.gov/pubmed/34230841>
 129. Kripalani, Y., Lakkappan, V., Parulekar, L., Shaikh, A., Singh, R., & Vyas, P. (2021). A Rare Case of Guillain-Barre Syndrome following COVID-19 Vaccination. *Eur J Case Rep Intern Med*, 8(9), 002707. doi:10.12890/2021_002797. <https://www.ncbi.nlm.nih.gov/pubmed/34671572>
 130. Leung, C. (2021). Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2. *Hum Vaccin Immunother*, 17(9), 2957-2958. doi:10.1080/21645515.2021.1922061. <https://www.ncbi.nlm.nih.gov/pubmed/34032555>

131. Maramattom, B. V., Krishnan, P., Paul, R., Padmanabhan, S., Cherukudal Vishnu Nampoothiri, S., Syed, A. A., & Mangat, H. S. (2021). Guillain-Barre Syndrome following ChAdOx1-S/nCoV-19 Vaccine. *Ann Neurol*, 90(2), 312-314. doi:10.1002/ana.26143. <https://www.ncbi.nlm.nih.gov/pubmed/34114256>
132. McKean, N., & Chircop, C. (2021). Guillain-Barre syndrome after COVID-19 vaccination. *BMJ Case Rep*, 14(7). doi:10.1136/bcr-2021-244125. <https://www.ncbi.nlm.nih.gov/pubmed/34330729>
133. Min, Y. G., Ju, W., Ha, Y. E., Ban, J. J., Lee, S. A., Sung, J. J., & Shin, J. Y. (2021). Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. *J Neuroimmunol*, 359, 577691. doi:10.1016/j.jneuroim.2021.577691. <https://www.ncbi.nlm.nih.gov/pubmed/34416410>
134. Mokhashi, N., Narla, G., & Marchionni, C. (2021). Guillain-Barre Syndrome in a Patient With Asymptomatic Coronavirus Disease 2019 Infection and Major Depressive Disorder. *Cureus*, 13(3), e14161. doi:10.7759/cureus.14161. <https://www.ncbi.nlm.nih.gov/pubmed/33927956>
135. Morehouse, Z. P., Paulus, A., Jasti, S. A., & Bing, X. (2021). A Rare Variant of Guillain-Barre Syndrome Following Ad26.COV2.S Vaccination. *Cureus*, 13(9), e18153. doi:10.7759/cureus.18153. <https://www.ncbi.nlm.nih.gov/pubmed/34703690>
136. Nasuelli, N. A., De Marchi, F., Cecchin, M., De Paoli, I., Onorato, S., Pettinaroli, R., . . . Godi, L. (2021). A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. *Neurol Sci*, 42(11), 4747-4749. doi:10.1007/s10072-021-05467-w. <https://www.ncbi.nlm.nih.gov/pubmed/34272622>
137. Nishiguchi, Y., Matsuyama, H., Maeda, K., Shindo, A., & Tomimoto, H. (2021). Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. *BMC Neurol*, 21(1), 452. doi:10.1186/s12883-021-02489-x. <https://www.ncbi.nlm.nih.gov/pubmed/3478919>
138. Oo, W. M., Giri, P., & de Souza, A. (2021). AstraZeneca COVID-19 vaccine and Guillain-Barre Syndrome in Tasmania: A causal link? *J Neuroimmunol*, 360, 577719. doi:10.1016/j.jneuroim.2021.577719. <https://www.ncbi.nlm.nih.gov/pubmed/34560365>
139. Prasad, A., Hurlburt, G., Podury, S., Tandon, M., Kingree, S., & Sriwastava, S. (2021). A Novel Case of Bifacial Diplegia Variant of Guillain-Barre Syndrome Following Janssen COVID-19 Vaccination. *Neurol Int*, 13(3), 404-409. doi:10.3390/neurolint13030040. <https://www.ncbi.nlm.nih.gov/pubmed/34449715>
140. Razok, A., Shams, A., Almeer, A., & Zahid, M. (2021). Post-COVID-19 vaccine Guillain-Barre syndrome; first reported case from Qatar. *Ann Med Surg (Lond)*, 67, 102540. doi:10.1016/j.amsu.2021.102540. <https://www.ncbi.nlm.nih.gov/pubmed/34249353>
141. Rosenblum, H. G., Hadler, S. C., Moulia, D., Shimabukuro, T. T., Su, J. R., Tepper, N. K., . . . Oliver, S. E. (2021). Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021. *MMWR Morb Mortal Wkly Rep*, 70(32), 1094-1099. doi:10.15585/mmwr.mm7032e4. <https://www.ncbi.nlm.nih.gov/pubmed/34383735>
142. Rossetti, A., Gheihman, G., O'Hare, M., & Kosowsky, J. M. (2021). Guillain-Barre Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report. *J Emerg Med*, 61(6), e141-e145. doi:10.1016/j.jemermed.2021.07.062. <https://www.ncbi.nlm.nih.gov/pubmed/34538679>
143. Samudralwar, R. D. (2021). Commentary: The spectrum of neurological manifestations related to COVID-19 and vaccinations. *J Neuroimmunol*, 358, 577660. doi:10.1016/j.jneuroim.2021.577660. <https://www.ncbi.nlm.nih.gov/pubmed/34274719>
144. Scendon, R., Petrelli, C., Scaloni, G., & Logullo, F. O. (2021). Electromyoneurography and laboratory findings in a case of Guillain-Barre syndrome after second dose of Pfizer COVID-19 vaccine. *Hum Vaccin Immunother*, 1-4. doi:10.1080/21645515.2021.1954826. <https://www.ncbi.nlm.nih.gov/pubmed/34347563>
145. Sebghati, M., & Khalil, A. (2021). Uptake of vaccination in pregnancy. *Best Pract Res Clin Obstet Gynaecol*, 76, 53-65. doi:10.1016/j.bpobgyn.2021.03.007. <https://www.ncbi.nlm.nih.gov/pubmed/33965331>
146. Shao, S. C., Wang, C. H., Chang, K. C., Hung, M. J., Chen, H. Y., & Liao, S. C. (2021). Guillain-Barre Syndrome Associated with COVID-19 Vaccination. *Emerg Infect Dis*, 27(12), 3175-3178. doi:10.3201/eid2712.211634. <https://www.ncbi.nlm.nih.gov/pubmed/34648420>

147. Shasha, D., Bareket, R., Sikron, F. H., Gertel, O., Tsamir, J., Dvir, D., . . . Zacay, G. (2022). Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. *Clin Microbiol Infect*, 28(1), 130-134. doi:10.1016/j.cmi.2021.09.018. <https://www.ncbi.nlm.nih.gov/pubmed/34592420>
148. Sriwastava, S., Shrestha, A. K., Khalid, S. H., Colantonio, M. A., Nwafor, D., & Srivastava, S. (2021). Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. *Neurol Int*, 13(4), 622-639. doi:10.3390/neurolint13040061. <https://www.ncbi.nlm.nih.gov/pubmed/34842783>
149. Tutar, N. K., Eyigurbuz, T., Yildirim, Z., & Kale, N. (2021). A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN. *Ideggyogy Sz*, 74(7-08), 286-288. doi:10.18071/isz.74.0286. <https://www.ncbi.nlm.nih.gov/pubmed/34370408>
150. Woo, E. J., Mba-Jonas, A., Dimova, R. B., Alimchandani, M., Zinderman, C. E., & Nair, N. (2021). Association of Receipt of the Ad26.COVS COVID-19 Vaccine With Presumptive Guillain-Barre Syndrome, February-July 2021. *JAMA*, 326(16), 1606-1613. doi:10.1001/jama.2021.16496. <https://www.ncbi.nlm.nih.gov/pubmed/34617967>